Core Points - The company announced a cash dividend of 1.10 RMB per share for A shares [1][3] - The total cash dividend to be distributed amounts to approximately 162.97 million RMB, based on the total shares eligible for distribution [3][4] Dividend Distribution Details - The record date for the dividend is set for June 17, 2025, with the last trading day and ex-dividend date both on June 18, 2025 [3][5] - The total share capital of the company is 154,542,928 shares, with 6,384,860 shares in the repurchase account, resulting in 148,158,068 shares eligible for the dividend [3][4] - The cash dividend distribution will not include shares held in the repurchase account [5] Tax Implications - For individual shareholders holding shares for over one year, the dividend income is exempt from personal income tax, resulting in a net cash dividend of 1.10 RMB per share [7] - For shares held for one year or less, the company will not withhold personal income tax at the time of distribution, but tax will be calculated upon the sale of the shares [7][8] - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, leading to a net cash dividend of 0.99 RMB per share [8]

Group 1 - The company plans to sell 100% equity of its subsidiary, Qinghai Zhongyou Health Huijia Pharmaceutical Chain Co., Ltd., to Jilin Province Zhiyu Technology Co., Ltd. for a price of 100 million RMB [2] - The company has received 70 million RMB of the equity transfer payment and transferred 51% of the equity to Zhiyu Technology, but due to the failure of Zhiyu Technology to pay the remaining amount, the company has filed a lawsuit [3] - The company provided loans totaling 14.6 million RMB to Qinghai Huijia during its operation, which are to be repaid by December 31, 2024, but due to non-repayment, the company has initiated arbitration [4] Group 2 - On June 9, 2025, Zhiyu Technology paid 20 million RMB of the equity transfer payment as per the civil mediation agreement, while Qinghai Huijia paid the first installment of 3,981,842 RMB to the company [5] - The company will cooperate with Zhiyu Technology to complete the equity and business registration changes and will urge Qinghai Huijia to fulfill its remaining payment obligations as per the settlement agreement [6]

Core Viewpoint - Anhui Huaren Health Pharmaceutical Co., Ltd. plans to acquire equity stakes in three pharmacy chains for a total of 327 million yuan, aiming to enhance its market share and brand influence in East China [1][2] Group 1: Acquisition Details - The company intends to purchase 46.01% of Fujian Yangzuo Huimin Pharmaceutical Chain Co., Ltd. for 133.4 million yuan, 46.01% of Fujian Haihua Pharmaceutical Chain Co., Ltd. for 125.1 million yuan, and 70.01% of Tonglu Yishengtang Pharmacy Chain Co., Ltd. for 68.3 million yuan [2] - The funding for the acquisitions will come from the company's own funds and a change in the use of part of the raised funds, with 130 million yuan allocated for the acquisitions if approved [2] Group 2: Financial Performance and Valuation - The estimated revenue and net profit for the acquired companies in 2024 are as follows: Yangzuo Huimin 294 million yuan revenue and 5.615 million yuan net profit, Haihua Pharmaceutical 270 million yuan revenue and 11.056 million yuan net profit, and Yishengtang 96.46 million yuan revenue and 0.264 million yuan net profit [3] - The valuation increase rates for the acquired companies are significant: Yangzuo Huimin at 892.79%, Haihua Pharmaceutical at 1029.4%, and Yishengtang at 2350.84% [3] Group 3: Growth and Expansion - Since its listing in March 2023, the company has conducted 22 asset purchase transactions totaling over 1 billion yuan, with major investments including 876 million yuan for five significant equity investments [4] - The company has expanded its store count significantly, adding 440 stores in 2024, with a total of 1,774 stores by the end of the year [6] Group 4: Shareholder Activity - Despite the company's growth, it has faced significant shareholder sell-offs, with major shareholders reducing their stakes, including Alibaba Health and Huatai Health [7][8] - The company has stated that these sell-offs are based on the shareholders' operational and financial needs, and management remains confident in the company's future [8]

Meeting Overview - The annual general meeting of shareholders was held on May 21, 2025, at the company's headquarters in Kunming, Yunnan Province [2] - The meeting was convened by the board of directors and chaired by the chairman, Mr. Lan Bo, in compliance with the Company Law and the company's articles of association [2] Attendance and Voting - All 7 current directors and 3 supervisors attended the meeting, along with the board secretary and the general manager [3] - There were no rejected resolutions during the meeting [2] Resolutions Passed - The following resolutions were approved: - 2024 Annual Board Work Report [3] - 2024 Annual Supervisory Work Report [3] - 2024 Annual Independent Director Work Report [4] - 2024 Financial Settlement Report [4] - 2025 Financial Budget Plan [4] - 2024 Profit Distribution Plan [4] - Approval of the 2024 Annual Report and its summary [4] - Reappointment of the auditing firm for 2025 [4] - Approval for the company and its subsidiaries to apply for comprehensive credit lines and provide guarantees [4] - Approval of the estimated related party transactions for 2025 [5] Legal Verification - The meeting was witnessed by Beijing Deheng (Kunming) Law Firm, confirming that the meeting's convening, attendance, and voting procedures complied with legal and regulatory requirements [5]

本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 安徽华人健康医药股份有限公司（以下简称"公司"或"华人健康"或"上 市公司"）于2025年5月19日召开的第五届董事会第九次会议和第五届监事会第 八次会议，审议通过了《关于变更募集资金用途的议案》，同意公司结合现阶段 发展需求及公司整体经营发展布局等实际情况变更部分募集资金用途。现将具体 情况公告如下： 一、本次变更募集资金投资项目的概述 证券代码：301408 证券简称：华人健康 公告编号：2025-036 安徽华人健康医药股份有限公司 （一）募集资金基本情况 经中国证券监督管理委员会《关于同意安徽华人健康医药股份有限公司首次 公开发行股票注册的批复》（证监许可20222406号）的同意注册，公司获准向 社会公众发行人民币普通股A股6,001.00万股，每股面值人民币1元。截至2023 年3月1日止，本公司已向社会公众发行人民币普通股A股6,001.00万股，每股发 行价格16.24元，募集资金总额为人民币974,562,400.00元。扣除承销费等发行 费用（不含本次公开发行股票发行费用可抵扣增值税进项税额）人 ...

证券代码：301408 证券简称：华人健康 公告编号：2025-037 安徽华人健康医药股份有限公司 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 截至 2025 年 5 月 8 日，公司募集资金投入募投项目具体情况如下： | 单位：万元 | | | | | | --- | --- | --- | --- | --- | | 拟使用募集资金 | | | | 累计已投入募集 | | 募集资金投资项目 项目投资总额 | 序号 | | | | | 投入金额 | | | | 资金 | | 支付舟山里肯医药连锁 | | | | | | 有限公司股权收购款 | | | | | | 60,567.80 合计 | | | 60,567.80 | 35,224.04 | | 三、前次使用闲置募集资金临时补充流动资金的基本情况 | | | | | | 公司于 2024 6 月 24 日召开了第五届董事会第三次会议和第五届监事会第 | | 年 | | | | 三次会议，审议通过了《关于使用闲置募集资金临时补充流动资金的议案》，同 | | | | | 安徽华人健康医药股份有限公司（以 ...

核查意见 华泰联合证券有限责任公司 关于安徽华人健康医药股份有限公司使用闲置募集资金临 时补充流动资金的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作 为安徽华人健康医药股份有限公司（以下简称"华人健康"或"公司"）首次公 开发行股票并在创业板上市持续督导阶段的保荐人，根据《证券发行上市保荐业 务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求》 《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》及《深圳证券交易所上市公司自 律监管指引第 13 号——保荐业务》等有关规定，对华人健康使用闲置募集资金 临时补充流动资金事项进行了核查，具体核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意安徽华人健康医药股份有限公司首次 公开发行股票注册的批复》（证监许可20222406 号）同意注册，公司获准向社 会公众发行人民币普通股 A 股 6,001.00 万股，每股面值人民币 1 元。截至 2023 年 3 月 1 日止，公司已向社会公众发行人民币普通股 A 股 6,001 ...

北京德恒（昆明）律师事务所 关于健之佳医药连锁集团股份有限公司 法律意见 北京德恒（昆明）律师事务所 Beijing DeHeng Law Offices (KunMing) 云南省昆明市西山区西园路 126 号"融城优郡"B5 幢 3、4 层 北京德恒（昆明）律师事务所 关于健之佳医药连锁集团股份有限公司 法 律 意 见 健之佳医药连锁集团股份有限公司： 北京德恒（昆明）律师事务所（下称"本所"）作为贵公司的常年法律顾问， 本次指派王琳律师、谢峰律师出席贵公司 2024 年年度股东会（以下简称"本次 股东会"），并按照律师行业公认的业务标准、道德规范及勤勉尽责精神，对贵 公司提供的与本次股东会有关的文件资料进行了审查，现根据《中华人民共和国 公司法》《中华人民共和国证券法》《上市公司股东会规则》及贵公司《章程》 的规定，就贵公司本次股东会的相关问题出具如下法律意见： 一、关于本次股东会的召集和召开程序 根据贵公司提供的有关资料及公开披露的信息，表明贵公司已于2025年4月 日在《中国证券报》《上海证券报》《证券时报》《证券日报》和巨潮资讯网 （http://www.cninfo.com.cn）等媒体刊登了召 ...

中国经济网北京5月19日讯健之佳（605266）(605266.SH)2024年年度报告显示，2024年，公司实现营业收入92.83亿元，同比增长 2.23%；归属于上市公司股东的净利润1.28亿元，同比下降69.08%；归属于上市公司股东的扣除非经常性损益的净利润1.24亿 元，同比下降68.89%；经营活动产生的现金流量净额为5.09亿元，同比下降50.32%。 健之佳发行募集资金总额为96,579.25万元，募集资金净额为87,450.16万元。健之佳2020年10月27日发布的招股说明书显示，健之 佳拟募集资金87,450.16万元，分别用于新开门店建设项目、医药连锁信息服务项目、全渠道多业态营销平台建设项目。 健之佳发行费用总额(不含税)为9,129.09万元，承销费用为6743.44万元，保荐费用为400万元。 健之佳2022年4月22日发布的非公开发行股票发行情况报告书显示，2022年4月13日，主承销商红塔证券已将扣除保荐和承销费后 的上述认购款划转至健之佳开立的募集资金专用账户。信永中和会计师事务所(特殊普通合伙)出具了XYZH/2022KMAA20033号 《验资报告》，确认发行人募集资金 ...

近日，公司完成了减少注册资本的工商变更登记及修订《公司章程》的工商备案手续，并取得云南省市 场监督管理局换发的《营业执照》。 证券代码：605266 证券简称：健之佳 公告编号：2025-030 健之佳医药连锁集团股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据健之佳医药连锁集团股份有限公司（以下简称"公司"）2024年第二次临时股东会审议通过的《关于 终止实施2024年限制性股票激励计划暨回购注销限制性股票的议案》、《关于修订〈公司章程〉的议 案》，公司终止实施2024年限制性股票激励计划，回购并注销对261名激励对象已授予但尚未解除限售 的2,117,880股限制性股票，需变更注册资本、修订公司章程、办理工商变更登记。 本次回购、注销手续于2025年4月17日完成，注销后公司总股本由156,660,808股减少至154,542,928股。 具体内容详见于2025年4月19日在上海证券交易所网站（www.sse.com.cn）披露的《关于限制性股票回 购注销完成的公 ...